Results 221 to 230 of about 2,312,760 (293)

Post‐Pyloric Enteral Immunoglobulin for Treatment of Chronic Norovirus Diarrhea in Solid Organ Transplant Recipients: A Single Center Retrospective Study

Transplant Infectious Disease, EarlyView.
Post‐pyloric enteral Ig was associated with 100% resolution of diarrhea in our small cohort of solid organ transplant recipients with chronic norovirus diarrhea refractory to commonly used interventions like immunosuppression reduction, nitazoxanide, and IVIg.
Fahad Buskandar, Andrew H. Karaba, Brandon Trollinger, Robin K. Avery   +3 more
wiley   +1 more source

Graph neural networks in the nephropathological diagnosis of antibody-mediated rejection. [PDF]

Comput Struct Biotechnol J
Mateos-Aparicio-Ruiz I, Pedraza A, Altini N, Gonzalez L, Bueno G.   +4 more
europepmc   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

Transfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman, Meghana Vivek, Rida Hasan, Siobán Keel, Laura Connelly‐Smith   +4 more
wiley   +1 more source

Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes. [PDF]

BMC Nephrol
Yilmaz B, Uslu A, Taşli F, Durusoy R, Doğan SM, Okut G, Uğur MA, Kocabaş E.   +7 more
europepmc   +1 more source

Development of a systematic drug screening method for cord blood donation for transfusion to extremely preterm neonates

Transfusion, EarlyView.
Abstract Background Cord blood‐derived red blood cell transfusions (CB‐RBCs) are being developed for extremely preterm neonates to preserve physiological fetal hemoglobin levels. We assessed how standard blood donor medication screening could be adapted for this novel donor population.
Jip H. van Daelen, Elise M. A. Slob, Elise J. Huisman, Irwin K. M. Reiss, Enrico Lopriore, Alex Eggink, Anna L. M. J. van der Knijff ‐ van Dortmont, Thomas R. L. Klei, Masja de Haas, Asghar Zeinali Lathori, Zahraa Hasan, Pauline M. Snijder, Robert B. Flint   +12 more
wiley   +1 more source

Amyloid β alters vascular CaV1.2 channel spatiotemporal properties

The Journal of Physiology, EarlyView.
Abstract figure legend Amyloid‐β1‐42 (Aβ1‐42) triggers a male‐specific signalling cascade influencing CaV1.2 spatiotemporal properties in cerebral vascular smooth muscle. The signalling pathway involves NADPH oxidase (NOX)‐derived reactive oxygen species (ROS) activation of protein kinase C (PKC). Aβ1‐42 can also activate protein kinase A (PKA).
Jade L. Taylor, Miguel Martin‐Aragon Baudel, Eric Pereira da Silva, Johannes W. Hell, Madeline Nieves‐Cintron, Manuel F. Navedo   +5 more
wiley   +1 more source

Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection: An Analysis of the Surveillance HeartCare Outcomes Registry. [PDF]

JACC Heart Fail
Kim PJ, Alam AH, Teuteberg JJ, Khush KK, Pinney SP, Cheng RK, Yehya A, Kobulnik J, Pinney KM, Oreschak KA, Ensor CR, Fan S, Urey MA, Shah P, Hall SA.   +14 more
europepmc   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

Journal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet, O. Moranne, D. Daubin, X. Quantin, P. Palassin, T. Kanouni, A. T. J. Maria, the MonRIO network (Montpellier Réseau Immuno‐Oncologie), Q. Thomas, P. Witkowski Durand Viel, C. Coustal, S. Faure, L. Meunier, L. Hountondji, R. Altwegg, C. Lesage, A. Lamoureux, G. Mouterde, S. Fabre, G. Taieb, F. Esselin, X. Ayriginac, C. Travert, B. Roch, F. Roubille, I. Raingeard, M. Le Quintrec, K. Dessaix, F. Garo, O. Moranne, J‐L. Faillie, P. Palassin, K. Klouche, B. Jauzelon, S. Bisiou, P. Rozier, A. TJ Maria   +36 more
wiley   +1 more source

One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection. [PDF]

Clin Kidney J
Etiève R, Van Wynsberghe M, Grangé S, Laurent C, Lemoine M, Candon S, Bertrand D, de Nattes T.   +7 more
europepmc   +1 more source